Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01832259 · ClinicalTrials.gov registry record · Phase 2
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
A Phase 2 study of Adenocarcinoma of the Prostate, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01832259: Completed Phase 2 study of Adenocarcinoma of the Prostate, sponsored by University of Utah.
NCT01832259 is a Phase 2 study of Adenocarcinoma of the Prostate that has completed, run by University of Utah. The registered enrollment target is 30 participants, below the 108-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01832259, a Phase 2 study of Adenocarcinoma of the Prostate, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they can predict which future patients may benefit from this therapy. The purpose of this study is to see if the drug pazopanib can be used to reduce the amount of pre-metastatic niche in the patient's lymph nodes (a common site for prostate cancer to spread). Down the line, this may help to prevent prostate cancer from coming back after surgery.
Primary Outcome
Patients with high-risk, localized prostate cancer were treated with 28 days of Pazopanib or placebo, after which they underwent radical prostatectomy. During prostatectomy, benign pelvic lymph node tissue was collected and subsequently analyzed for the average number of VEGFR1-positive clusters in 8 distinct 40x microscopic fields as an indicator of pre-metastatic niche formation.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pazopanib
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-08-09 |
| Phase | Phase 2 |
What the finished NCT01832259 record still lists
NCT01832259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 108-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01832259 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT01832259 about?
NCT01832259 is a clinical study titled "A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection". The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they can predict which future patients may benefit from this therapy. The pur...
What is the current status of trial NCT01832259?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-08. Estimated completion is 2018-08-09.
What conditions does trial NCT01832259 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT01832259?
The interventions under investigation include: Placebo (OTHER), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01832259?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01832259 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01832259's enrollment target sits among peer trials
30 14th of 21 higher than 8 of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
COMPLETED · Phase 2
-
Enzalutamide in Patients With High-risk Prostate Cancer
COMPLETED · Phase 2
-
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
COMPLETED · Phase 2
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
COMPLETED · Phase 2
-
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia